Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab + Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer

<div>PFS (a) and OS (b) survival curves of patients with different pleural effusion CD4<sup>+</sup>/CD8<sup>+</sup> ratios in the treatment group.</div>

Journal of Oncology

fig6

Figure 6

Figure 6: Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab + Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer 

Figure 6 | Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab + Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer 